On Jun. 29, 2021, Paratek Pharmaceuticals announced it had delivered the first procurement of NUZYRA to the Biomedical Advanced Research and Development Authority (BARDA) for the treatment of pulmonary anthrax. This procurement was valued at ~$38 million.

In December 2019, BARDA awarded Paratek a five-year contract, valued at up to $284.5 million, to support: 1) the development of NUZYRA for the treatment of pulmonary anthrax; 2) U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval; 3) U.S. onshoring of NUZYRA and manufacturing security requirements, and 4) up to four procurements of NUZYRA. As described above, BARDA had taken title of the first procurement under the contract.